A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters.
Kathryn McGuckin WuertzErica K BarkeiWei-Hung ChenElizabeth J MartinezInes Lakhal-NaouarLinda L JagodzinskiDominic Paquin-ProulxGregory D GromowskiIsabella SwaffordAkshaya GaneshMing DongXiankun ZengPaul V ThomasRajeshwer S SankhalaAgnes HajduczkiCaroline E PetersonCaitlin KuklisSandrine SomanLindsay WieczorekMichelle ZemilAlexander AndersonJanice DardenHeather HernandezHannah GroveVincent DussuptHolly HackRafael de la BarreraStasya ZarlingJames F WoodJeffrey W FroudeMatthew GagneAmy R HenryElham Bayat MokhtariPrakriti MudvariShelly J KrebsAndrew S PekoszJeffrey R CurrierSwagata KarMaciel PortoAdrienne WinnKamil RadzyminskiMark G LewisSandhya VasanMehul S SutharVictoria R PolonisGary R MatyasEli A BoritzDaniel C DouekRobert A SederSharon P DayeMangala RaoSheila A PeelM Gordon JoyceDiane L BoltonNelson L MichaelKayvon ModjarradPublished in: bioRxiv : the preprint server for biology (2021)
The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the B.1.1.7 and B.1.351 VOCs in Syrian golden hamsters. SpFN-ALFQ was administered as either single or double-vaccination (0 and 4 week) regimens, using a high (10 μg) or low (0.2 μg) immunogen dose. Animals were intranasally challenged at week 11. Binding antibody responses were comparable between high- and low-dose groups. Neutralizing antibody titers were equivalent against WA1, B.1.1.7, and B.1.351 variants following two high dose two vaccinations. SpFN-ALFQ vaccination protected against SARS-CoV-2-induced disease and viral replication following intranasal B.1.1.7 or B.1.351 challenge, as evidenced by reduced weight loss, lung pathology, and lung and nasal turbinate viral burden. These data support the development of SpFN-ALFQ as a broadly protective, next-generation SARS-CoV-2 vaccine.
Keyphrases
- sars cov
- low dose
- high dose
- respiratory syndrome coronavirus
- copy number
- weight loss
- bariatric surgery
- drug delivery
- type diabetes
- clinical trial
- electronic health record
- stem cell transplantation
- randomized controlled trial
- insulin resistance
- adipose tissue
- skeletal muscle
- gene expression
- dna methylation
- risk factors
- roux en y gastric bypass
- placebo controlled
- transcription factor
- iron oxide
- endothelial cells
- study protocol